Guardian Pharmacy Services Inc. (Class A) (GRDN) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (20% profit margin, 38% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-02, Guardian Pharmacy Services Inc. (Class A) (NYSE: GRDN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $40.69 (+0.59% 1D, market cap $2.56B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 15/20. Across 146 tracked Consumer Staples issuers, GRDN ranks #11 in composite RQD confidence.
Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), GRDN carries a Roarable B- (71/100 RQD), trailing P/E of 52.1x, gross margin of 20.2%, and ROIC of 37.7%. By comparison, CVS (CVS Health Corporation) holds a C- grade (61/100 RQD, P/E 65.3x, ROIC 2.6%, cap $115.53B) and YI (111 Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -20.5%, cap $26.2M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).
Per GRDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802255), Guardian Pharmacy Services Inc. (Class A) generated $1.45B in revenue (+17.9% YoY), $49.2M in net income, and $100.3M in free cash flow against $412.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (20% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 52x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 12.39 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL FY 2025 (10-K): 6.9% FCF Margin ($100.3M FCF) & 20.2% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)
Even with a 71/100 (B-) score, GRDN faces multiple-compression risk if 52.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Priced at 52x earnings—high expectations leave less room for a lukewarm quarter.
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 17.7% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($41.10) or 200D SMA ($38.14) invalidates the momentum regime and cuts Target Base ($43.07) toward Bear Floor ($33.37).
Guardian Pharmacy Services Inc. (Class A) (GRDN) advanced +0.59% to $40.69, trading at 65% of its 52-week range ($26.34 – $48.33). High-quality cash engine (20% profit margin, 38% return on capital) with steady institutional support.
Yahoo Finance report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +17.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GRDN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GRDN. Explore sector supply chains on /butterfly.
Across 146 tracked Consumer Staples securities in the Roarable RQD universe, Guardian Pharmacy Services Inc. (Class A) (GRDN) ranks #11 by composite RQD confidence (71/100, grade B-) and #53 by equity capitalization ($2.56B). Within this direct 5-issuer industry benchmark cohort, GRDN leads on earnings valuation at 52.1x trailing P/E, while GRDN leads on capital efficiency and profitability with 37.7% ROIC and 20.2% gross margin. GRDN currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GRDN
ACTIVE
Guardian Pharmacy Services Inc. (Class A) | B- | 71/100 | 52.1x | 20.2% | 37.7% | +0.59% | $2.56B | Benchmark Subject |
| CVS CVS Health Corporation | C- | 61/100 | 65.3x | 45.0% | 2.6% | -0.09% | $115.53B | /cvs-vs-grdn → |
| YI 111 Inc. | D- | 37/100 | — | 5.8% | -20.5% | -4.36% | $26.2M | /yi-vs-grdn → |
| PETS PetMed Express Inc. | E | 19/100 | — | 28.1% | -35.0% | +0.85% | $25.6M | /pets-vs-grdn → |
| RDGT Ridgetech Inc. | D- | 37/100 | — | 3.6% | — | -3.32% | $3.0M | /rdgt-vs-grdn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Guardian Pharmacy Services Inc. (Class A) (GRDN) reported GAAP revenue of $1.45B (+17.9% vs. FY2024 revenue of $1.23B ) , GAAP net income of $49.2M, operating cash flow of $100.3M, and free cash flow of $100.3M (+73.0% YoY). On the balance sheet, GRDN closed FY2025 with $412.7M in total assets against $0 in total debt (Altman Z-Score: 12.39, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.45B | $49.2M | $100.3M | $100.3M | $412.7M | — |
| FY2024 (FY) | 2024-12-31 | $1.23B | -$110.0M | $58.0M | $58.0M | $320.8M | — |
As of 2026-11-02, Guardian Pharmacy Services Inc. (Class A) (NYSE: GRDN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $40.69 (+0.59% 1D, market cap $2.56B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 15/20. Across 146 tracked Consumer Staples issuers, GRDN ranks #11 in composite RQD confidence.
Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), GRDN carries a Roarable B- (71/100 RQD), trailing P/E of 52.1x, gross margin of 20.2%, and ROIC of 37.7%. By comparison, CVS (CVS Health Corporation) holds a C- grade (61/100 RQD, P/E 65.3x, ROIC 2.6%, cap $115.53B) and YI (111 Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -20.5%, cap $26.2M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).
Per GRDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802255), Guardian Pharmacy Services Inc. (Class A) generated $1.45B in revenue (+17.9% YoY), $49.2M in net income, and $100.3M in free cash flow against $412.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (20% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 52x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
GRDN last traded at $40.69 (+0.59% on volume of 319,046 shares), positioning the stock -1.00% below its 50-day simple moving average ($41.10) and +6.69% above its 200-day simple moving average ($38.14). Across its 52-week range of $26.34 to $48.33, GRDN sits at the 65.3% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±7.3% ($37.72 to $43.66).
Why GRDN Stock advanced +0.59% Today — RQD Quant Desk Flash. High-quality cash engine (20% profit margin, 38% return on capital) with steady institutional support.
Per the Roarable RQD rating, GRDN carries an RQD Score of 71 and a letter grade of B-, labeled "Roarable Buy — Sound Institutional Accumulation." The five pillars are:
Investor implications. The rating's upside case rests on the cash engine and balance sheet. The valuation tradeoff is significant: per the market data, P/E (TTM) is 52.1 and EV/EBITDA is 34.3, well above typical levels, while FCF yield is 3.91%. The stock has also moved sharply within its 52-week range ($26.34–$48.33), with the current price of $40.45 near the upper portion of that band. The RQD score of 71 is therefore a composite of strong fundamentals and a demanding price, not an endorsement of valuation headroom. The whale-flow and macro pillars score lower, indicating less conviction from institutional and macro inputs.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-12-31) | $1448.7M | $72.7M | $49.2M | N/A | $100.3M | $65.6M | N/A |
| FY 2024 (filed 2024-12-31) | $1228.4M | $-62.9M | $-110.0M | N/A | $58.0M | $4.7M | N/A |
Per the SEC financials, revenue rose from $1228.4M in FY 2024 to $1448.7M in FY 2025, and the company moved from an operating loss of $-62.9M and net loss of $-110.0M to operating income of $72.7M and net income of $49.2M. Per the market data, gross margin is 20.2%, operating margin 5%, and net margin 3.4%, with ROIC of 37.7%. Per the RQD rating, the Altman Z-Score is 12.39 and the Piotroski F-Score is 7/9, with Debt/Equity of 0.5. Balance sheet detail (debt and EPS line items) is not itemized in the reported periods.
Risk watch items: The valuation commentary ("may trade at a discount," "fully priced") indicates that the market has already priced in part of the upside. Proprietary signals: None are listed in the Butterfly Supply-Chain Graph.
Real-time company headlines, analyst actions, and sector developments for Guardian Pharmacy Services Inc. (Class A) (GRDN) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.
Welcome to the GRDN (Guardian Pharmacy Services Inc. (Class A)) Roar Pit. Current RQD Composite is 71/100 (Roarable Buy — Sound Institutional Accumulation) in Retail-Drug Stores and Proprietary Stores. Bulls point to capital efficiency (37.7% ROIC), while bears focus on valuation multiple compression (52.1x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on GRDN, but look at what you are paying: 52.1x trailing P/E with 20.2% gross margins. Unless Guardian Pharmacy Services Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on GRDN, the market is fixating on short-term headline noise in Retail-Drug Stores and Proprietary Stores and ignoring the balance sheet and cash flow trajectory. At $40.45 (52-wk range $26.34 - $48.33), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).